SPLIO
14.3.2023 08:01:58 CET | Business Wire | Press release
Splio, CRM expert and developer of the SaaS Individuation® marketing platform, is proud to announce the acquisition of Tinyclues, the specialist in SaaS predictive marketing based on deep learning AI. This acquisition fulfills a shared ambition to enable brands to easily orchestrate large-scale, hyper-personalized marketing plans.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230314005122/en/
On the left, David Bessis (Tinyclues) and on the right, Mireille Messine (Splio) (Photo: Splio)
Splio works with more than 400 brands, including Decathlon, Longchamp and Orange, and has been developing its own Individuation® marketing solution since 2021. Based on machine learning (AI), this solution addresses the dual challenge currently faced within CRM: how to personalize the customer experience for each individual whilst offering marketers a simple solution for large-scale orchestration.
The technological power of the Tinyclues platform increases the value proposition of Splio. A recent winner of both the Sammy and MarTech Breakthrough awards, Tinyclues is currently the most powerful predictive engine on the market, since it is the only one fueled by deep learning. It allows for the automated processing of huge volumes of first-party data for precise customer behaviour prediction. Over 100 brands use Tinyclues on a daily basis, including Veepee, Fnac, Accor, Samsung, Tiffany & Co and SNCF Connect.
The acquisition of Tinyclues thus enables Splio to establish itself as the European leader in AI-powered CRM thanks to its Individuation® marketing software, which can be rapidly and easily deployed across all industries and for companies of all sizes.
“AI has become the new standard for better understanding customers and personalizing large-scale marketing communications regardless of industry or business size. Individuation® marketing based on machine learning was an initial response to these challenges. The Tinyclues platform, based on deep learning, strengthens our leadership, and provides new opportunities for sectoral and geographical growth.” Mireille Messine, CEO of Splio.
“For a long time, Splio and Tinyclues have shared the same vision of CRM and the same ‘one-to-one at scale’ ambition for clients. Joining Splio enables our deep learning platform to express its full potential by allowing brands to carry out predictive marketing, including customer management and activation.” David Bessis, CEO of Tinyclues.
As a result of this acquisition, Splio now has 250 employees in Europe and the MEA and a portfolio of 500 business clients, from medium-sized companies to large groups from a large range of industries (retail, restaurant, telecoms, travel, hotel, leisure, etc.) with an annual recurring revenue over €30m.
About Splio
Splio is a Martech company headquartered in Paris, with 200 employees, 90 of whom work in Product and R&D, and five offices in Europe and the MEA.
Splio provides a SaaS Individuation® marketing platform to B2C customer marketing professionals. The company has a portfolio of more than 400 brands, from medium-sized enterprises to major groups from four key industries (retail, e-commerce, restaurant and telecom), including Longchamp, Decathlon, Rue du Commerce, Nicolas, Brioche Dorée and Orange.
Splio aims to empower marketing automation with Individuation® enabling companies to activate and engage each of their customers on a case-by-case basis in a unique relationship using AI.
The Individuation® marketing platform is based on a one-of-a-kind innovation that automates each day the most relevant communications to the most appropriate channels for each one of a companies’ customers. The platform is uniquely capable of calculating the optimum based both on a company’s objectives and on the appetencies of each of its customers.
Mireille Messine is the CEO of Splio and Gregory Chapron the Co-CEO. Investors include Sofiouest, Ring Capital, BPI-FAN, Omnes, Seventure, Amundi PEF, BNP Paribas Développement and SWEN.
About Tinyclues
Tinyclues is a Martech company whose precision-AI targets individuals based on buying propensity. Over 100 brands currently use the solution, including Veepee, Fnac, Accor, Samsung, Tiffany & Co and SNCF Connect.
Tinyclues’ cutting-edge technology analyses often-ignored first-party data signals so that CRM teams can accurately predict customer purchase intent and easily orchestrate complex marketing plans.
Tinyclues was the winner of the Sammy Award for Product of the Year in 2021 and the Martech Breakthrough Award for Best CRM Solution for Enterprises in 2021 and 2022. Tinyclues has been listed as a ‘Vendor to Watch’ in Gartner’s Magic Quadrant for Digital Marketing Analytics and as a ‘Cool Vendor’ within its Multichannel Marketing Report. In addition, G2 awarded Tinyclues the ‘Users Love Us’ and ‘High Performer’ certificates in 2021 and 2022.
Tinyclues’ investors include ISAI, Elaia, Alven Capital and EQT Ventures.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230314005122/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Egon Zehnder Names Ayşe Güçlü Onur Global Human Resources Practice Leader2.9.2026 15:00:00 CEST | Press release
Egon Zehnder has appointed Ayşe Güçlü Onur as Global Leader of its Human Resources Practice. This appointment comes as companies and boards increasingly look to CHROs to help shape business strategy, lead transformation, build leadership pipelines, and navigate major shifts in culture and the workforce. "CHROs used to be evaluated by how well they supported the business. Today, the best drive it," said Onur. "Our role is to help CHROs move from a seat at the table to a hand in business growth. We help them connect leadership decisions, talent, and culture directly to elevated performance. That's the shift Egon Zehnder is built to guide with our leadership advisory services." Egon Zehnder’s Human Resources Practice partners with companies to discover, develop, and transform future-ready CHROs, helping them shape the future of the function. This includes executive search, leadership assessment and development, board effectiveness, culture, succession planning, organizational transformati
Safe Software to Increase Global Headcount by Over 15% as Demand for AI-Ready Data Grows2.9.2026 15:00:00 CEST | Press release
The FME creator is recruiting for more than 60 roles across the UK, US and Canada before the end of December, less than a year after crossing $100M in revenue Safe Software, the creator of FME, the only All-Data, Any-AI enterprise integration platform with true support for spatial data, today announced it is recruiting for more than 60 roles throughout the remainder of 2026. The hiring will take the company past 400 employees, increasing headcount by over 15%, with new positions across the United Kingdom, the United States and Canada. The expansion follows a year in which Safe crossed $100 million in annual revenue, growing close to 20 percent year over year and moving ahead of schedule on its target of $250 million by 2028. The company also grew its employee base by over 20% in the same period. "The incredible growth that we’ve seen over the last 30+ years at Safe has always been a testament to the great people behind what we do," said Don Murray, Co-Founder and CEO of Safe Software.
Owkin to License K Pro AI Scientist and Multimodal Oncology and Immunology Datato Boehringer Ingelheim2.9.2026 14:00:00 CEST | Press release
Owkin, the agentic AI company striving to transform drug discovery and development for biopharma, today announced a license agreement with Boehringer Ingelheim for K Pro, Owkin’s AI Scientist, together with multimodal patient data, aiming to speed up the discovery process across multiple indications in oncology and immunology. This agreement builds upon an initial pilot undertaken by Owkin with Boehringer in 2025. In that pilot Owkin delivered deep spatial insights into the tumor microenvironment of a gene target through its MOSAIC dataset. Under the new agreement, Owkin will license multimodal oncology data to Boehringer and will generate new multimodal data in immunology. Owkin licenses, sources and generates multimodal patient data in collaboration with its global patient data network. Boehringer Ingelheim’s teams will access and analyze this data through K Pro, which provides a single environment to interrogate data and run reproducible analyses. K Pro’s reasoning capabilities supp
Biocytogen Enters into Non-Exclusive Licensing Agreement with Qilu Pharmaceutical for a Fully Human VHH Antibody to Support Innovative Drug Development in Neuroscience2.9.2026 14:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, SSE: 688796; HKEX: 02315) today announced that it has entered into a non-exclusive licensing agreement with Qilu Pharmaceutical Co., Ltd. (“Qilu Pharmaceutical”) for a fully human VHH antibody molecule. Under the agreement, Biocytogen will grant Qilu Pharmaceutical non-exclusive rights to a fully human VHH antibody molecule to support its research and development of innovative therapeutics in the neuroscience field. The licensed VHH antibody molecule was generated from Biocytogen’s proprietary RenNano® platform. The RenNano® platform is designed to discover fully human VHH antibody molecules with favorable specificity, binding affinity, and developability, and can generate molecular building blocks for the design and development of VHH antibodies, bispecific/multispecific antibodies, antibody-drug conjugates, and other innovative modalities. Through this license, Qilu Pharmaceutical may advance the research and development o
Croma-Pharma Introduces Electronic Instructions for Use Across the saypha® Portfolio2.9.2026 13:37:00 CEST | Press release
Healthcare professionals in eligible markets can now access the Instructions for Use for the saypha® portfolio digitally by scanning a QR code on the product packaging Croma-Pharma has introduced electronic Instructions for Use (eIFU) across its saypha® portfolio in markets where applicable regulations permit electronic Instructions for Use to replace printed versions. The transition expands digital access to essential product information for healthcare professionals while reducing the use of printed documentation. Healthcare professionals can access the current approved Instructions for Use by scanning the QR code on the saypha® folding box. The eIFU platform provides direct digital access to the latest approved Instructions for Use. "Innovation extends beyond product development. It also includes how we provide healthcare professionals with access to essential product information," said Andreas Prinz, Chief Executive Officer of Croma-Pharma. "The introduction of electronic Instructio
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
